标题
Disease-modifying strategies for Parkinson's disease
作者
关键词
-
出版物
MOVEMENT DISORDERS
Volume 30, Issue 11, Pages 1442-1450
出版商
Wiley
发表日期
2015-07-24
DOI
10.1002/mds.26354
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system
- (2015) Katrina L. Paumier et al. EXPERIMENTAL NEUROLOGY
- Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease
- (2015) Karl Kieburtz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- (2015) Reina N. Fuji et al. Science Translational Medicine
- Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model
- (2014) Shih-Chun Ho et al. BEHAVIOURAL BRAIN RESEARCH
- Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)
- (2014) Raghava R Kethiri et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy
- (2014) J. Schapansky et al. HUMAN MOLECULAR GENETICS
- Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice
- (2014) J. Mark Cooper et al. MOVEMENT DISORDERS
- Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic
- (2014) Andrew B. West MOVEMENT DISORDERS
- Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
- (2014) Mike A Nalls et al. NATURE GENETICS
- Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation
- (2014) Xuelai Fan et al. NATURE NEUROSCIENCE
- Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
- (2014) Veronica Lindström et al. NEUROBIOLOGY OF DISEASE
- Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
- (2014) B. Ritz et al. NEUROLOGY
- Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation
- (2014) Luis Fonseca-Ornelas et al. Nature Communications
- α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
- (2014) Hien T. Tran et al. Cell Reports
- Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
- (2014) Michael A. Schwarzschild et al. JAMA Neurology
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
- (2014) et al. JAMA Neurology
- Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro
- (2013) Paolo Ruzza et al. ACS Chemical Neuroscience
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
- (2013) Jens Wagner et al. ACTA NEUROPATHOLOGICA
- Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys
- (2013) Ariadna Recasens et al. ANNALS OF NEUROLOGY
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
- (2013) Anthony HV Schapira et al. LANCET NEUROLOGY
- Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model
- (2013) Tanya Chotibut et al. MOLECULAR NEUROBIOLOGY
- Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
- (2013) MOVEMENT DISORDERS
- Lysosomal impairment in Parkinson's disease
- (2013) Benjamin Dehay et al. MOVEMENT DISORDERS
- Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
- (2013) R. T. Bartus et al. NEUROLOGY
- Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
- (2013) Amaal AlDakheel et al. Neurotherapeutics
- TFEB-mediated autophagy rescues midbrain dopamine neurons from -synuclein toxicity
- (2013) M. Decressac et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The prion hypothesis in Parkinson's disease: Braak to the future
- (2013) Naomi P Visanji et al. Acta Neuropathologica Communications
- Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein
- (2013) Amanda N Sacino et al. Acta Neuropathologica Communications
- Meta-analysis of early nonmotor features and risk factors for Parkinson disease
- (2012) Alastair J. Noyce et al. ANNALS OF NEUROLOGY
- α-Synuclein oligomers and clinical implications for Parkinson disease
- (2012) Lorraine V. Kalia et al. ANNALS OF NEUROLOGY
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Urate in Parkinson’s Disease: More Than a Biomarker?
- (2012) Xiqun Chen et al. Current Neurology and Neuroscience Reports
- Calcium, Bioenergetics, and Neuronal Vulnerability in Parkinson's Disease
- (2012) D. James Surmeier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
- (2012) Kelvin C. Luk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway
- (2012) Li Gong et al. JOURNAL OF NEUROCHEMISTRY
- Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans
- (2012) Gusheng Wu et al. JOURNAL OF NEUROSCIENCE RESEARCH
- A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients
- (2012) Jay S. Schneider et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain
- (2012) J W Steele et al. MOLECULAR PSYCHIATRY
- Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease
- (2012) Katrina L. Paumier et al. MOVEMENT DISORDERS
- Caffeine for treatment of Parkinson disease: A randomized controlled trial
- (2012) R. B. Postuma et al. NEUROLOGY
- Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration
- (2012) X. Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
- (2012) M. Decressac et al. Science Translational Medicine
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
- (2011) Susan H. Fox et al. MOVEMENT DISORDERS
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
- (2011) E. Ilijic et al. NEUROBIOLOGY OF DISEASE
- Mice Lacking Major Brain Gangliosides Develop Parkinsonism
- (2011) Gusheng Wu et al. NEUROCHEMICAL RESEARCH
- Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers
- (2011) C. Marras et al. NEUROLOGY
- Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases
- (2010) Maurizio Renna et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- (2010) William J Marks et al. LANCET NEUROLOGY
- Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains
- (2010) Raymond T. Bartus et al. MOVEMENT DISORDERS
- Glutathione—a review on its role and significance in Parkinson’s disease
- (2009) Heather L. Martin et al. FASEB JOURNAL
- Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response
- (2008) Mahmoud M. Iravani et al. EXPERIMENTAL NEUROLOGY
- Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
- (2008) William J Marks et al. LANCET NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search